Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 37 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

43%

16 trials in Phase 3/4

Results Transparency

0%

0 of 22 completed trials have results

Key Signals

14 recruiting

Enrollment Performance

Analytics

Phase 3
12(32.4%)
Phase 1
10(27.0%)
N/A
6(16.2%)
Phase 2
5(13.5%)
Phase 4
4(10.8%)
37Total
Phase 3(12)
Phase 1(10)
N/A(6)
Phase 2(5)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (37)

Showing 20 of 37 trials
NCT07421011Phase 1Recruiting

Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 mg Tablets in Healthy Volunteers.

Role: lead

NCT07420985Phase 2Recruiting

Study to Evaluate the Efficacy, Safety, and Tolerability of the Ingavirin Forte Capsules (Valenta Pharm JSC) at Different Doses in Subjects With Influenza and Other Acute Respiratory Viral Infections.

Role: lead

NCT06342778Phase 1Completed

Pharmacokinetics and Bioequivalence of Doxylamine+Pyridoxine and Diclectin Under Fed Conditions in Healthy Volunteers

Role: lead

NCT06842966Phase 2Recruiting

Efficacy, Safety, and Tolerability of 4-MUST Tablets in Chronic Cholecystitis and Biliary Dyskinesia

Role: lead

NCT06859281Phase 1Recruiting

Safety, Tolerability, and Pharmacokinetic Profile of Grammidin, a Metered Dose Topical Spray in Healthy Volunteers

Role: lead

NCT06843018Phase 2Recruiting

Study to Evaluate the Efficacy and Safety of Different Doses of Graminidin With Anesthetic, a Metered Dose Topical Spray, in the Treatment of Acute Infectious and Inflammatory Pharyngeal Diseases Compared With Drug Septolete Total, Lozenges

Role: lead

NCT06857890Phase 1Recruiting

Safety, Tolerability, and Pharmacokinetic Profile of Grammidin With Anesthetic, a Metered Dose Topical Spray in Healthy Volunteers

Role: lead

NCT06843044Phase 4Recruiting

Efficacy and Safety of Ranquilon in Patients With Anxiety Disorders Due to Neurasthenia and Adjustment Disorders

Role: lead

NCT06859333Phase 1Recruiting

Study of the Safety, Tolerability, and Pharmacokinetic Profile of Ascending Doses of Ingavirin Forte, Capsules, Folliwing Single and Subsequent Multiple Oral Administration in Healthy Volunteers

Role: lead

NCT06321341Phase 4Recruiting

Efficacy and Safety of Vespireit, Prolonged-release Tablets, in Patients With Autonomic Dysfunction Syndrome Accompanied by Functional Vertigo

Role: lead

NCT06552624Not ApplicableCompleted

Comparative Pharmacodynamics and Pharmacodynamics Equivalence of Antareit 800 mg Chewable Tablets and Riopan 800 mg Chewable Tablets in Healthy Volunteers

Role: lead

NCT06098742Not ApplicableRecruiting

Comparative Pharmacodynamics and Pharmacodynamics Equivalence of Antareit 800 mg/10 ml Oral Suspension and Riopan 800 mg Chewable Tablets in Healthy Volunteers

Role: lead

NCT06379542Phase 3Recruiting

Efficacy and Safety of XC8, Film-coated Tablets, in Children With Acute Respiratory Viral Infections

Role: lead

NCT06342804Phase 1Recruiting

Food Effect on the Bioavailability of 4-MUST, Tablets, 128 mg

Role: lead

NCT06315400Phase 4Recruiting

Efficacy and Safety of Ingavirin®, Capsules, 60 mg, in Children With Influenza and Other Acute Respiratory Viral Infections

Role: lead

NCT06096571Not ApplicableUnknown

Pharmacokinetics and Bioequivalence of Aterixen 100 mg Tablets and Aterixen 100 mg Film-coated Tablets in Healthy Volunteers

Role: lead

NCT06315387Phase 1Recruiting

Safety, Tolerability and Pharmacokinetics of 4-MUST, Tablets, 128 mg (Valenta Pharm JSC) During Single and Multiple Oral Administration in Healthy Volunteers

Role: lead

NCT05544916Phase 3Completed

A Study to Evaluate the Safety and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory Infections

Role: lead

NCT05558462Not ApplicableCompleted

Pharmacokinetics and Bioequivalence of XC8 10 mg and 40 mg Tablets in Fasted Volunteers

Role: lead

NCT05561816Phase 3Completed

Efficacy and Safety of Dioxidin Versus Miramistin in Superficial Pyoderma

Role: lead